OBJECTIVES: To estimate lifetime health benefits of mobocertinib and current treatment options for patients with locally advanced or metastatic non-small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutation (EGFRex20ins-mNSCLC) who had progressed on or after platinum-based chemotherapy in China.

METHODS: A partitioned survival model with three health states and lifetime time horizon was developed to estimate progression-free life years (PFLYs), post-progression life years (PPLYs), disutility life years due to adverse events, and to calculate quality-adjusted life years (QALY) for mobocertinib, docetaxel plus cisplatin (DTX/CDDP), docetaxel plus cisplatin and bevacizumab (DTX/CDDP/BEV), pemetrexed plus cisplatin (PEM/CDDP), pemetrexed plus cisplatin and bevacizumab (PEM/CDDP/BEV) and high-dose osimertinib in patients with EGFRex20ins-mNSCLC in China. The literature was searched to identify appropriate model inputs. Unadjusted single-arm meta-analysis was used to synthesize the identified evidence. If no specific data for post-platinum EGFRex20ins-mNSCLC existed, evidence on same race (i.e., Asian) and second-line treatment of NSCLC was used. One-way and probabilistic sensitivity analyses (OWSA and PSA) were performed to assess the robustness of the results and parameters’ uncertainty.

RESULTS: In the base-case analysis, mobocertinib could gain 0.722 (vs. PEM/CDDP/BEV) to 0.862 years (vs. high-dose osimertinib) of PFLYs, 1.269 (vs. high-dose osimertinib) to 1.993 years (vs. DTX/CDDP) of PPLYs, and 1.713 (vs. high-dose osimertinib) to 2.266 incremental QALYs (vs. DTX/CDDP). The OWSA showed that the QALYs gained with mobocertinib relative to other treatments were mainly driven by additional PFLYs and PPLYs, the influential parameters included survival outcomes (PFS and overall survival) of the compared treatments and the utility of health states. Mobocertinib has the probability of 100.0% vs. all the comparators to gain more QALYs based on the PSA.

CONCLUSIONS: Mobocertinib had additional lifetime health benefits (PFLYs, PPLYs, and QALYs) compared with existing, second-line treatments of EGFRex20ins-mNSCLC in China. Results were robust to variations in the OWSA and PSA.